Merger Notification - Announcement according to § 10 Cartel Act
Baxter Healthcare SA; Cilag GmbH International
BWB/Z-5212
On 15.01.2021 the Austrian Federal Competition Authority was notified of the following merger:
Planned purchase process
Baxter Healthcare SA (Glattpark / Switzerland) intends to acquire certain assets relating to the drug Caelyx from Cilag GmbH International (Zug / Switzerland), a group company of Johnson & Johnson. The proposed concentration concerns a drug used for the treatment of certain types of cancer.
Affected industry: Manufacture of pharmaceutical preparations
Industry sector: C - Verarbeitendes Gewerbe/Herstellung von Waren
Deadline for bringing in an application pursuant to § 11(1) Cartel Act will end on 12.02.2021.
Entrepreneurs whose legal or economic interests are affected by the merger can bring in a written statement at the Federal Competition Authority or the Federal Cartel Prosecutor within 14 days from publication date.
Note: The intervening party has no right to a certain treatment of the statement and will not gain a party position.
Non-prohibition of the merger
The Federal Competition Authority and the Federal Cartel Prosecutor have not applied for examination of the merger by the Cartel Court. The standstill obligation (§ 17 (1) Cartel Act) ends with effect from 13.02.2021 .